Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2021 Earnings Conference Call July 29, 2021 6:00 PM ET Company Participants Edward Chung - Head of IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andrew Last - EVP and COO Annette Tumolo - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Jack Meehan - Nephron Research Operator Good afternoon, ladies and gentlemen, and welco ...

公司整体净销售额变化 - 2021年前六月公司净销售额为14.4亿美元，较2020年同期的11.1亿美元增长30.1%，排除外汇影响增长约25.4%[139] - 2021年第二季度公司净销售额为7.159亿美元，较2020年同期的5.369亿美元增长33.4%，排除外汇影响增长约27.5%[125] 生命科学部门销售额变化 - 2021年前六月生命科学部门销售额为7.007亿美元，较去年同期增长46.2%，货币中性基础上增长41.1%[140] - 2021年第二季度生命科学部门销售额为3.342亿美元，较去年同期增长32.6%，货币中性基础上增长27.1%[126] 临床诊断部门销售额变化 - 2021年前六月临床诊断部门销售额为7.388亿美元，较去年同期增长18.5%，货币中性基础上增长14.1%[141] - 2021年第二季度临床诊断部门销售额为3.802亿美元，较去年同期增长34.3%，货币中性基础上增长28.0%[127] 综合毛利率变化 - 2021年前六月综合毛利率为55.6%，2020年同期为55.1%；第二季度综合毛利率为56.1%，2020年同期为54.6%[121] 公司重组计划情况 - 2021年2月公司宣布战略驱动的重组计划，预计2022年底基本完成，截至6月30日，重组应计费用为6160万美元[120] 利息费用变化 - 2021年前六月和第二季度利息费用分别为80万美元和40万美元，2020年同期分别为1140万美元和570万美元，主要因2020年12月偿还4.25亿美元优先票据本金[131][145] 有效所得税税率变化 - 2021年第二季度和前六月公司有效所得税税率分别为21.0%和22.4%，税率降低主要因某些法规时效到期释放准备金[135] - 2021年和2020年上半年有效所得税税率分别为22.9%和23.0%[149] 外汇净收益变化 - 2021年上半年外汇净收益为170万美元，2020年上半年为净损失170万美元[146] 股权证券公允价值变动收益变化 - 2021年和2020年上半年股权证券公允价值变动收益分别为22.1亿美元和20.1亿美元[147] 其他收入净额变化 - 2021年上半年其他收入净额为1730万美元，2020年上半年为2050万美元，减少320万美元[148] 公司信贷安排情况 - 截至2021年6月30日，公司有2亿美元无担保循环信贷安排，无未偿还借款，但有20万美元用于国内备用信用证[151] 公司现金及投资情况 - 截至2021年6月30日，公司有11.7亿美元现金、现金等价物和短期投资，约31%由海外子公司持有[153] 经营活动净现金变化 - 2021年和2020年截至6月30日的六个月，经营活动提供的净现金分别为2.682亿美元和1.549亿美元[156] 投资活动净现金变化 - 2021年和2020年截至6月30日的六个月，投资活动使用的净现金分别为1.486亿美元和1.01亿美元[158] 融资活动净现金变化 - 2021年和2020年截至6月30日的六个月，融资活动使用的净现金分别为4450万美元和1.016亿美元[159] 公司股票回购情况 - 2021年第一季度，公司以5000万美元回购89506股A类普通股，2020年以1亿美元回购291941股[160]

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2021 Earnings Conference Call April 29, 2021 6:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Annette Tumolo - EVP & President, Life Science Group Dara Wright - EVP & President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Daniel Leonard - Wells Fargo Securities Patrick Donnelly - Citigroup Nisarg Shah - Nephron Operator L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2020 Earnings Conference Call February 11, 2021 6:00 PM ET Corporate Participants Ron Hutton - Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Annette Tumolo - President of the Life Science Group Dara Wright - President of the Clinical Diagnostics Group Conference Call Participants Dan Leonard - Wells Fargo Brandon Couillard - Jeffe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange ☐ TRANSITION REPORT PURSUANT TO SECTION ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2020 Earnings Conference Call October 29, 2020 6:00 PM ET Company Participants Kevin Han - IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Annette Tumolo - EVP & President, Life Science Group Conference Call Participants Patrick Donnelly - Citigroup Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Securities Jack Meehan - Nephron Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2020 Earnings Conference Call July 30, 2020 6:00 PM ET Company Participants Kevin Han - Senior Director, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Annette Tumolo - President of Life Science Group Dara Wright - President of the Clinical Diagnostics Group Conference Call Participants Dan Leonard - Wells Fargo Patrick Don ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...